• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

    4/22/25 8:30:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SRPT alert in real time by email

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial results after the Nasdaq Global Market closes on Tuesday, May 6, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2025 financial results.

    The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

    About Sarepta Therapeutics

    Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.

    Internet Posting of Information

    We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250422222092/en/

    Investor Contact:

    Ian Estepan, 617-274-4052

    [email protected]

    Media Contact:

    Tracy Sorrentino, 617-301-8566

    [email protected]

    Get the next $SRPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRPT

    DatePrice TargetRatingAnalyst
    5/8/2025$50.00Outperform → In-line
    Evercore ISI
    4/11/2025$115.00Overweight
    Wells Fargo
    4/2/2025$75.00Sell → Neutral
    H.C. Wainwright
    3/31/2025$161.00 → $87.00Outperform → Sector Perform
    RBC Capital Mkts
    2/11/2025$136.00Hold
    Deutsche Bank
    11/27/2024$205.00 → $202.00Buy
    Needham
    11/25/2024$80.00Sell
    H.C. Wainwright
    11/7/2024$152.00 → $167.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SRPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

      Net product revenues for the first quarter 2025 totaled $611.5 million, a 70% increase over the same quarter of the prior year ELEVIDYS net product revenue for the first quarter totaled $375.0 million; Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $4.0 million Revised 2025 total net product revenues guidance to $2.3 to $2.6 billion Meaningfully advanced multiple clinical candidates in limb-girdle muscular dystrophy portfolio Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025. "In the first quarter, we achieved net product revenue of $611.5 mi

      5/6/25 4:05:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

      Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial results after the Nasdaq Global Market closes on Tuesday, May 6, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone

      4/22/25 8:30:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

      –      U.S. FDA has confirmed that screening and dosing may proceed in Study SRP-9005-101 for LGMD2C/R5 –      Enrollment and dosing completed in Study SRP-9004-102 for LGMD2D/R3 –      Data expected for SRP-9003 for LGMD2E/R4 by mid-2025 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates from its clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5, 2D/R3, and 2E/R4. SRP-9005 for LGMD type 2C/R5: Following input from the U.S. Food and Drug Administration (FDA), Office of Therapeutic Products (OTP), Sarepta is cleared to proceed with dosing in Study SRP-9005-101 (COMPASS) in the U.S. CO

      4/15/25 8:30:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sarepta Therapeutics downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Sarepta Therapeutics from Outperform to In-line and set a new price target of $50.00

      5/8/25 8:27:43 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Sarepta Therapeutics with a new price target

      Wells Fargo initiated coverage of Sarepta Therapeutics with a rating of Overweight and set a new price target of $115.00

      4/11/25 9:10:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Sarepta Therapeutics from Sell to Neutral and set a new price target of $75.00

      4/2/25 8:22:16 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      8/20/24 8:00:04 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barry Richard bought $3,940,500 worth of shares (50,000 units at $78.81) (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      11/6/23 8:00:11 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ingram Douglas S bought $2,001,800 worth of shares (25,225 units at $79.36), increasing direct ownership by 7% to 390,307 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      11/6/23 8:00:10 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Financials

    Live finance-specific insights

    See more
    • Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

      Net product revenues for the first quarter 2025 totaled $611.5 million, a 70% increase over the same quarter of the prior year ELEVIDYS net product revenue for the first quarter totaled $375.0 million; Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $4.0 million Revised 2025 total net product revenues guidance to $2.3 to $2.6 billion Meaningfully advanced multiple clinical candidates in limb-girdle muscular dystrophy portfolio Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025. "In the first quarter, we achieved net product revenue of $611.5 mi

      5/6/25 4:05:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

      Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial results after the Nasdaq Global Market closes on Tuesday, May 6, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone

      4/22/25 8:30:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

      – Net product revenues for the fourth quarter 2024 totaled $638.2 million, a 75% increase over the same quarter of the prior year – ELEVIDYS net product revenue for the quarter totaled $384.2 million; Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $4.9 million – Achieved GAAP and non-GAAP net income of $159.0 million and $206.0 million for the fourth quarter of 2024, respectively Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2024. "2024 performance represented the fruition of our multi-year strategy to become a self-sustaining pro

      2/26/25 4:05:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Nicaise Claude exercised 9,746 shares at a strike of $25.18 and sold $248,203 worth of shares (2,491 units at $99.64), increasing direct ownership by 35% to 27,812 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      3/13/25 8:00:04 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Boor Kathryn Jean was granted 2,383 shares, increasing direct ownership by 41% to 8,263 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      3/11/25 8:00:18 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Connelly Deirdre P was granted 2,383 shares, increasing direct ownership by 84% to 5,225 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      3/11/25 8:00:20 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

      7/12/24 4:40:36 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

      For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

      6/20/24 5:24:42 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

      6/5/24 4:41:31 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Sarepta Therapeutics Inc.

      10-Q - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      5/6/25 4:01:26 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Sarepta Therapeutics Inc.

      DEFA14A - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      4/24/25 4:10:03 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Sarepta Therapeutics Inc.

      DEF 14A - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      4/24/25 4:05:17 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

      SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

      11/13/24 10:27:59 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sarepta Therapeutics Inc.

      SC 13G - Sarepta Therapeutics, Inc. (0000873303) (Subject)

      2/9/24 6:05:54 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sarepta Therapeutics Inc. (Amendment)

      SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

      2/14/23 3:23:55 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

      - Veteran biopharmaceutical executive from GSK and Eli Lilly brings more than 30 years of experience to Sarepta's Board Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly's appointment, Sarepta's Board will comprise nine directors, eight of whom are independent. "Ms. Connelly is a seasoned board leader with extensive operating experience in biopharma and we're pleased to welcome her to the Sarepta Board of Directors as we work to

      9/16/24 8:30:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

      Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

      7/17/24 8:00:00 AM ET
      $MDXG
      $SAVA
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics Set to Join S&P MidCap 400

      NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For

      5/29/24 5:48:00 PM ET
      $JNJ
      $SPGI
      $SRPT
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance